Bellerophon Therapeutics (NASDAQ:BLPH) Issues Earnings Results

Bellerophon Therapeutics (NASDAQ:BLPH) released its quarterly earnings results on Monday. The biotechnology company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.13, Fidelity Earnings reports.

Shares of BLPH traded up $0.05 during mid-day trading on Wednesday, reaching $4.05. The company’s stock had a trading volume of 327 shares, compared to its average volume of 76,117. The business has a 50-day simple moving average of $4.80 and a two-hundred day simple moving average of $6.75. Bellerophon Therapeutics has a 1-year low of $3.96 and a 1-year high of $21.28. The stock has a market cap of $38.50 million, a P/E ratio of -1.22 and a beta of -0.29.

In other news, major shareholder New Mountain Investments Ii, L sold 400,000 shares of the stock in a transaction dated Thursday, March 18th. The shares were sold at an average price of $5.48, for a total transaction of $2,192,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 38.50% of the company’s stock.

Separately, Zacks Investment Research downgraded shares of Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 16th.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading: How to find the components of the quick ratio

Earnings History for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.